AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Transient receptor potential cation channel subfamily M member 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9HCF6

UPID:

TRPM3_HUMAN

Alternative names:

Long transient receptor potential channel 3; Melastatin-2

Alternative UPACC:

Q9HCF6; A2A3F6; A9Z1Y7; Q5VW02; Q5VW03; Q5VW04; Q5W5T7; Q86SH0; Q86SH6; Q86UL0; Q86WK1; Q86WK2; Q86WK3; Q86WK4; Q86YZ9; Q86Z00; Q86Z01; Q9H0X2

Background:

Transient receptor potential cation channel subfamily M member 3 (TRPM3), also known as Long transient receptor potential channel 3 and Melastatin-2, plays a pivotal role in calcium ion entry. Its activity is modulated by various factors including extracellular osmolarity, store depletion, and muscarinic receptor activation. TRPM3 forms heteromultimeric ion channels with TRPM1, facilitating the permeation of calcium and zinc ions.

Therapeutic significance:

TRPM3 is implicated in neurodevelopmental disorders characterized by hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, and in Cataract 50 with or without glaucoma. These associations highlight its potential as a target for therapeutic intervention in these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.